MetaCap

Annovis Bio Inc. (ANVS)

NYSE: ANVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.7113-0.0371 (-4.96%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANVS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$44.12M
EPS (TTM)
-$1.55
52-week range
0.62 – 5.50
Day range
0.70 – 0.774
Volume / Avg
1.43M / 1.82M
Beta
—

52-week range

$0.62$5.50

ANVS stock today

On Nov 20, ANVS ended the session at $0.7113, shedding $0.0371 (4.96%), versus the S&P 500's 3.70% decline. At this level, ANVS sits near the bottom of its 52-week range of $0.62 to $5.50: 87.1% below the high, set on Nov 28, 2025 and 14.7% above the low. ANVS is down 79.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 81.2%.

Annovis Bio has posted a net loss over the last twelve months (EPS of -$1.55), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Annovis Bio

Company profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Maria L. Maccecchini Ph.D.
Headquarters
Malvern, PA
Employees
7
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Annovis Bio generated $0 in revenue, up 0.0% from fiscal 2024. Annovis Bio reported a net loss of $28.9 million, compared with a loss of $24.6 million a year earlier. Diluted earnings per share came in at -$1.40.

Annovis Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0$0$0$0
Growth—————
Net income$-28.85M$-24.59M$-56.20M$-25.33M$-14.49M
EPS (diluted)$-1.40$-2.31$-6.23$-3.10$-1.90

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$10.50+1376.17%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $17.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.22 vs $-0.30
Surprise
+26.67%

ANVS news

All ANVS news

Annovis Bio peers

Health Care sector
ANVS peer companies
CompanyPrice% ChgMarket capCompare
GANXGain Therapeutics Inc.0.9994-4.82%$44.50Mvs ANVS
QUCYQuantum Cyber N.V.0.512-7.25%$44.67Mvs ANVS
RLYBRallybio Corporation15.47-0.32%$43.32Mvs ANVS
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs ANVS
APLMApollomics Inc. Class A15.54-6.92%$45.28Mvs ANVS
RNXTRenovoRx Inc.0.942-10.29%$45.45Mvs ANVS
CRBPCorbus Pharmaceuticals Holdings Inc.2.06-15.40%$42.45Mvs ANVS
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs ANVS

Indexes, lists and sector

Annovis Bio stock FAQ

What is Annovis Bio's stock price today?

ANVS last traded at $0.7113 as of Nov 20, 4:00 PM EST, down 4.96% on the day. Prices are delayed at least 15 minutes.

Who is Annovis Bio's CEO?

Dr. Maria L. Maccecchini Ph.D. is the chief executive officer of Annovis Bio Inc., which has about 7 employees.

What is the ANVS 52-week high?

The 52-week high for ANVS is $5.50 and the 52-week low is $0.62. The stock is currently 87.1% below its high.

Compare ANVS